Maximus, Inc. (MMS) Lowered to Sell at Zacks Investment Research
Maximus, Inc. (NYSE:MMS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “
Other research analysts also recently issued research reports about the company. Robert W. Baird restated a “hold” rating and set a $64.00 price target on shares of Maximus in a research note on Friday, September 1st. Maxim Group set a $66.00 target price on Maximus and gave the company a “hold” rating in a research note on Thursday, August 3rd. Canaccord Genuity lowered their target price on Maximus from $62.00 to $61.00 and set a “hold” rating on the stock in a research note on Friday. Finally, BidaskClub downgraded Maximus from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating and seven have issued a hold rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $63.00.
Maximus (MMS) opened at $64.63 on Tuesday. The stock has a market capitalization of $4,089.63, a P/E ratio of 20.29, a P/E/G ratio of 1.99 and a beta of 1.32. Maximus has a 12 month low of $51.74 and a 12 month high of $66.96.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/11/14/maximus-inc-mms-lowered-to-sell-at-zacks-investment-research.html.
In related news, CEO Richard A. Montoni sold 29,203 shares of Maximus stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $60.38, for a total value of $1,763,277.14. Following the sale, the chief executive officer now directly owns 549,215 shares in the company, valued at $33,161,601.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Raymond B. Ruddy sold 25,000 shares of Maximus stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $60.39, for a total value of $1,509,750.00. Following the completion of the sale, the director now owns 252,552 shares in the company, valued at $15,251,615.28. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 137,103 shares of company stock worth $8,503,210. Company insiders own 3.10% of the company’s stock.
Several institutional investors have recently bought and sold shares of MMS. Acrospire Investment Management LLC boosted its stake in shares of Maximus by 17.6% in the second quarter. Acrospire Investment Management LLC now owns 2,000 shares of the health services provider’s stock valued at $125,000 after buying an additional 300 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Maximus by 10.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,367 shares of the health services provider’s stock worth $148,000 after purchasing an additional 220 shares during the last quarter. First Bank & Trust raised its holdings in Maximus by 4.2% during the second quarter. First Bank & Trust now owns 2,507 shares of the health services provider’s stock worth $157,000 after purchasing an additional 101 shares during the last quarter. Intl Fcstone Inc. acquired a new position in Maximus during the second quarter worth $201,000. Finally, GW Henssler & Associates Ltd. acquired a new position in Maximus during the second quarter worth $205,000. Hedge funds and other institutional investors own 97.55% of the company’s stock.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.